CORONA Remedies Q1FY27 Revenue Up 21.9% to ₹422.4 Cr, PAT Grows 30.1%
CORONA Remedies reported Q1FY27 revenue of ₹422.4 Cr, up 21.9% YoY. PAT grew 30.1% YoY to ₹60.1 Cr, with margins at 14.2%. The company inaugurated a new EU-GMP approved Female Hormone Manufacturing Facility on June 30, 2026. CORONA continues to outperform IPM growth.
The significant increase in revenue and profit, coupled with strategic business developments like the new manufacturing facility and market outperformance, indicates a strong positive impact on the company's financial health and market position.
The company reported strong year-on-year growth in revenue and profit, improved margins, and positive operational highlights like market rank progression and the inauguration of a new manufacturing facility.
CORONA Remedies Limited announced its unaudited financial results for the first quarter of FY27 (ended June 30, 2026). The company reported a revenue from operations of ₹422.4 crore, a significant increase of 21.9% year-on-year. Profit After Tax (PAT) for the quarter stood at ₹60.1 crore, marking a growth of 30.1% year-on-year. The PAT margin improved to 14.2%, up by 90 basis points compared to the same period last year.
The company highlighted its strong performance by outpacing the Indian Pharmaceutical Market (IPM) growth, ranking 26th as per MAT June'26. CORONA also holds a 5th rank in the Gynaecology therapy segment. A key development during the quarter was the inauguration and commercialization of its EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026. The integration of the acquired brand, Wokadine, from a supply and distribution perspective has also commenced.
Commenting on the results, Mr. Nirav K. Mehta, Managing Director & CEO of CORONA Remedies Limited, stated that the performance reflects the company's commitment to consistent growth through operational excellence and brand building. He added that the company aims to focus on core therapies like Women’s Healthcare, Cardio-diabetes, Pain Management, and Urology, while also strengthening its presence in the Infertility and Biosimilar segments.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.